î
îŒ
ãã°ã€ã³
î
PolyPid Ltd
PYPD4.280USD
-0.040-0.93%
çµå€Â 03/30, 16:00ïŒETïŒ15åé
ãã®æ ªäŸ¡
2.43Mæ䟡ç·é¡
æ倱é¡çŽè¿12ã¶æPER
î
詳现æ å ± PolyPid Ltd äŒæ¥å
Polypid Ltd is a biopharmaceutical company at the clinical stage, based in Israel . The company focuses on the development, production and commercialization of new, locally administered therapies to improve surgical results. The main product is PLEX technology, which is located in the place of surgery and ensures controlled and continuous delivery of medicines.
PolyPid Ltdã®äŒæ¥æ å ±
îäŒæ¥ã³ãŒãPYPD
äŒç€ŸåPolyPid Ltd
äžå Žæ¥Jun 26, 2020
æé«çµå¶è²¬ä»»è
ãCEOãAkselbrad (Dikla Czaczkes)
åŸæ¥å¡æ°57
蚌åžçš®é¡Ordinary Share
決ç®ææ«Jun 26
æ¬ç€Ÿæåšå°18 Hasivim Street, P.O Box 7126
éœåžPETAH TIKVA
蚌åžååŒæNASDAQ OMX - NASDAQ BASIC
åœIsrael
éµäŸ¿çªå·4917002
é»è©±çªå·972747195700
ãŠã§ããµã€ãhttps://www.polypid.com
äŒæ¥ã³ãŒãPYPD
äžå Žæ¥Jun 26, 2020
æé«çµå¶è²¬ä»»è
ãCEOãAkselbrad (Dikla Czaczkes)
PolyPid Ltdã®çµå¶é£
îäŒç€Ÿå
äŒç€Ÿå/ããžã·ã§ã³
ããžã·ã§ã³
æ ªåŒä¿æ
å€åé¡
Dr. Yechezkel Barenholz, Ph.D.
Dr. Yechezkel Barenholz, Ph.D.
Independent Director
Independent Director
2.76K
--
Ms. Dikla Czaczkes Akselbrad
Ms. Dikla Czaczkes Akselbrad
Chief Executive Officer, Director
Chief Executive Officer, Director
934.00
--
Dr. Itzhak Krinsky, Ph.D.
Dr. Itzhak Krinsky, Ph.D.
Independent Director
Independent Director
833.00
--
Mr. Jacob Harel
Mr. Jacob Harel
Independent Chairman of the Board
Independent Chairman of the Board
467.00
--
Mr. Ori Warshavsky
Mr. Ori Warshavsky
Chief Operating Officer - US
Chief Operating Officer - US
267.00
--
Dr. Noam Emanuel, Ph.D.
Dr. Noam Emanuel, Ph.D.
Chief Scientific Officer
Chief Scientific Officer
--
--
Mrs. Anat Tsour Segal
Mrs. Anat Tsour Segal
Independent Director
Independent Director
--
--
Dr. Shaul Mukhtar, Ph.D.
Dr. Shaul Mukhtar, Ph.D.
Chief Operating Officer, Executive Vice President
Chief Operating Officer, Executive Vice President
--
--
Ms. Dalit Hazan
Ms. Dalit Hazan
Senior Vice President - Research and Development and Regulatory Affairs
Senior Vice President - Research and Development and Regulatory Affairs
--
--
Mr. Nir Dror
Mr. Nir Dror
Independent Director
Independent Director
--
--
詳现ãèŠã
äŒç€Ÿå
äŒç€Ÿå/ããžã·ã§ã³
ããžã·ã§ã³
æ ªåŒä¿æ
å€åé¡
Dr. Yechezkel Barenholz, Ph.D.
Dr. Yechezkel Barenholz, Ph.D.
Independent Director
Independent Director
2.76K
--
Ms. Dikla Czaczkes Akselbrad
Ms. Dikla Czaczkes Akselbrad
Chief Executive Officer, Director
Chief Executive Officer, Director
934.00
--
Dr. Itzhak Krinsky, Ph.D.
Dr. Itzhak Krinsky, Ph.D.
Independent Director
Independent Director
833.00
--
Mr. Jacob Harel
Mr. Jacob Harel
Independent Chairman of the Board
Independent Chairman of the Board
467.00
--
Mr. Ori Warshavsky
Mr. Ori Warshavsky
Chief Operating Officer - US
Chief Operating Officer - US
267.00
--
Dr. Noam Emanuel, Ph.D.
Dr. Noam Emanuel, Ph.D.
Chief Scientific Officer
Chief Scientific Officer
--
--
åçå èš³
äŒç€Ÿããé¢é£ããŒã¿ããŸã é瀺ãããŠããŸããã
äŒç€Ÿããé¢é£ããŒã¿ããŸã é瀺ãããŠããŸããã
äºæ¥å¥
å°åå¥
äŒç€Ÿããé¢é£ããŒã¿ããŸã é瀺ãããŠããŸããã
æ ªäž»
æŽæ°æå»: Sat, Mar 14
æŽæ°æå»: Sat, Mar 14
æ ªäž»çµ±èš
çš®é¡
æ ªäž»çµ±èš
æ ªäž»çµ±èš
æ¯ç
Aurum Ventures M.K.I.
16.15%
Hodges (Rodney)
10.71%
AIGH Capital Management, LLC.
6.03%
Centaurus Investments Limited
5.80%
Rosalind Advisors, Inc.
3.65%
ä»ã®
57.65%
æ ªäž»çµ±èš
æ ªäž»çµ±èš
æ¯ç
Aurum Ventures M.K.I.
16.15%
Hodges (Rodney)
10.71%
AIGH Capital Management, LLC.
6.03%
Centaurus Investments Limited
5.80%
Rosalind Advisors, Inc.
3.65%
ä»ã®
57.65%
çš®é¡
æ ªäž»çµ±èš
æ¯ç
Venture Capital
16.33%
Individual Investor
15.53%
Hedge Fund
6.24%
Private Equity
6.03%
Holding Company
5.80%
Research Firm
1.22%
Investment Advisor
1.12%
Investment Advisor/Hedge Fund
1.00%
ä»ã®
46.73%
æ©é¢æè³å®¶ä¿ææ ª
îæŽæ°æå»: Thu, Jan 1
æŽæ°æå»: Thu, Jan 1
å ±åæé
æ©é¢æè³å®¶æ°
ä¿ææ ªåŒæ°
æ¯ç
å€åé¡
2025Q4
32
6.78M
40.77%
+1.48M
2025Q3
28
6.76M
43.18%
+2.23M
2025Q2
41
7.60M
74.58%
+1.39M
2025Q1
42
7.66M
75.16%
+942.60K
2024Q4
44
5.48M
65.20%
+1.87M
2024Q3
50
4.47M
69.98%
+1.49M
2024Q2
58
3.43M
73.51%
+1.59M
2024Q1
59
3.33M
71.29%
+2.56M
2023Q4
54
443.78K
34.10%
+80.67K
2023Q3
57
479.04K
37.01%
+97.48K
詳现ãèŠã
æ ªäž»åå
îäŒç€Ÿå
ä¿ææ ªåŒæ°
æ¯ç
å€åé¡
å€åç
æ¥ä»
Aurum Ventures M.K.I.
3.08M
18.53%
+1.06M
+52.19%
Jun 30, 2025
AIGH Capital Management, LLC.
771.59K
4.64%
+309.05K
+66.82%
Sep 30, 2025
Centaurus Investments Limited
1.11M
6.66%
+475.10K
+75.12%
Dec 31, 2024
Rosalind Advisors, Inc.
918.67K
5.52%
-56.79K
-5.82%
Sep 30, 2025
Nir (Yehuda)
613.91K
3.69%
+62.60K
+11.36%
Mar 31, 2025
Lukach (Aharon)
299.55K
1.8%
-5.64K
-1.85%
Mar 31, 2025
Morgan Stanley & Co. LLC
202.12K
1.22%
+124.69K
+161.03%
Sep 30, 2025
Dafna Capital Management, LLC
207.90K
1.25%
--
--
Sep 30, 2025
Worth Venture Partners, LLC
293.54K
1.76%
-438.03K
-59.88%
Sep 30, 2025
詳现ãèŠã
é¢é£ETF
îéæå
æ¯ç
ããŒã¿ãªã
é åœé
îéå»5幎éã®é
åœéç·æ¯æé¡ã¯
0.00
ç±³ãã«ã§ããã
æ¥ä»
é
åœé
æš©å©ç¢ºå®æ¥
æ¯ææ¥
é
åœèœã¡æ¥
ããŒã¿ãªã
æ ªåŒåå²
îæ¥ä»
é
åœèœã¡æ¥
çš®é¡
æ¯ç
Aug 30, 2023
Merger
30â1
Aug 30, 2023
Merger
30â1
Aug 30, 2023
Merger
30â1
Aug 30, 2023
Merger
30â1
æ¥ä»
é
åœèœã¡æ¥
çš®é¡
æ¯ç
Aug 30, 2023
Merger
30â1
Aug 30, 2023
Merger
30â1
Aug 30, 2023
Merger
30â1
Aug 30, 2023
Merger
30â1
